No-reflow phenomenon after acute myocardial infarction is associated with reduced clot permeability and susceptibility to lysis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 27, Issue 10, 2007, Pages 2258-2265

  Zalewski, Jaroslaw ^a,b   Undas, Anetta ^a   Godlewski, Jacek ^a,b   Stepien, Ewa ^b   Zmudka, Krzysztof ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

Author keywords

Fibrin clot; Fibrinolysis; Myocardial infarction; No reflow phenomenon; Primary coronary angioplasty

Indexed keywords

FIBRINOGEN; FIBRIN;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CARDIAC PATIENT; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; EPICARDIUM; FEMALE; FIBRIN CLOT; FIBRINOLYSIS; FOLLOW UP; HEART MUSCLE BLOOD FLOW; HEART MUSCLE PERFUSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; AGED; ANGIOCARDIOGRAPHY; BLOOD; CASE CONTROL STUDY; CORONARY ARTERY THROMBOSIS; ELECTROCARDIOGRAPHY; HEART INFARCTION; HOSPITALIZATION; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; PERMEABILITY; RISK ASSESSMENT; STATISTICAL MODEL; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CASE-CONTROL STUDIES; CORONARY ANGIOGRAPHY; CORONARY CIRCULATION; CORONARY THROMBOSIS; ELECTROCARDIOGRAPHY; FEMALE; FIBRIN; FIBRINOLYSIS; FOLLOW-UP STUDIES; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERMEABILITY; RESEARCH DESIGN; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 35148816461     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.107.149633     Document Type: Article

References (26)

1. Maes A, Van de Werf F, Nuyts J, Bormans G, Desmet W, Mortelmans L. Impaired myocardial tissue perfusion early after successful thrombolysis. Impact on myocardial flow, metabolism, and function at late follow-up. Circulation. 1995;92:2072-2078.
2. Gibson CM, Cannon CP, Murphy SA, Marble SJ, Barron HV, Braunwald E, TIMI Study Group. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 2000;101:125-130.
3. Matetzky S, Novikov M, Gruberg L, Freimark D, Feinberg M, Elian D, Novikov I, Di Segni E, Granat O, Har-Zahav Y, Rabinowitz B, Kaplinsky E, Hod H. The significance of persistent ST elevation versus early resolution of ST segment elevation after primary PTCA. J Am Coll Cardiol. 1999;34:1932-1938.
4. Kloner RA, Ganote CE, Jennings RB. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest. 1974;54:1496-1508.
5. Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B Jr, Marble SJ, McCabe CH, Raymond L, Fortin T, Poole WK, Braunwald E. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996;93:879-888.
6. Ito H, Maruyama A, Iwakura K, Takiuchi S, Masuyama T, Hori M, Higashino Y, Fujii K, Minamino T. Clinical implications of the "no-reflow" phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation. 1996;93:223-228.
7. Henriques JPS, Zijlstra F, Ottervanger JP, de Boer MJ, van 't Hof AW, Hoorntje JC, Suryapranata H. Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarction. Eur Heart J. 2002;23:1112-1117.
8. Laster SB, O'Keefe JH Jr, Gibbons RJ. Incidence and importance of thrombolysis in myocardial infarction grade 3 flow after primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol. 1996;78:623-626.
9. Feldman LJ, Himbert D, Juliard JM, Karrillon GJ, Benamer H, Aubry P, Boudvillain O, Seknadji P, Faraggi M, Steg G. Reperfusion syndrome: relationship of coronary blood flow reserve to left ventricular function and infarct size. J Am Coll Cardiol. 2000;35:1162-1169.
10. Anderson JL, Karagounis LA, Becker LC, Sorensen SG, Menlove RL. TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction. Ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 Study. Circulation. 1993;87:1829-1839.
11. Morishima I, Sone T, Okumura K, Tsuboi H, Kondo J, Mukawa H, Matsui H, Toki Y, Ito T, Hayakawa T. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol. 2000;36:1202-1209.
12. Michaels AD, Gibson CM, Barron HV. Microvascular dysfunction in acute myocardial infarction: focus on the roles of platelet and inflammatory mediators in the no-reflow phenomenon. Am J Cardiol 2000;85:50B-60B.
13. Blombäck B. Fibrinogen and fibrin-proteins with complex roles in hemostasis and thrombosis. Thromb Res. 1996;83:1-75.
14. Scott EM, Ariëns RA, Grant PJ. Genetic and environmental determinants of fibrin structure and function. Relevance to clinical disease. Arterioscler Thromb Vasc Biol. 2004;24:1558-1566.
15. Wu KC, Zerhouni EA, Judd RM, Lugo-Olivieri CH, Barouch LA, Schulman SP, Blumenthal RS, Lima JA. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation. 1998;97:765-772.
16. The TIMI study group. The thrombolysis in myocardial infarction (TIMI) trial. N Engl J Med 1993;312:932-936.
17. Schroder R, Dissmann R, Bruggemann T Wegscheider K, Linderer T, Tebbe U, Neuhaus KL. Extent of early ST segment elevation resolution: a simple but strong predictor of outcome in patients with acute myocardial infarction. J Am Coll Cardiol. 1994;24:384-391.
18. Mills JD, Ariëns RA, Mansfield MW, Grant PJ. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation. 2002;106:1938-1942.
19. Williams S, Fatah K, Ivert T, Blombäck M. The effect of acetylsalicylic acid on fibrin gel lysis by tissue plasminogen activator. Blood Coagul Fibrinolysis. 1995;6:718-725.
20. von dem Borne PA, Meijers JCM, Bouma BN. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood. 1995;86:3035-3042.
21. Lisman T, Leebeek FWG, Mosnier LO, Bouma BN, Meijers JC, Janssen HL, Nieuwenhuis HK, De Groot PG. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology. 2001;121:131-139.
22. Dunn EJ, Ariëns RA, de Lange M, Snieder H, Turney JH, Spector TD, Grant PJ. Genetics of fibrin clot structure: a twin study. Blood. 2004;103:1735-1740.
23. Dong J, Ndrepepa G, Schmitt C, Mehili J, Schmieder S, Schweiger M, Schoming M, Kastrati A. Early resolution of ST-segment elevation correlates with myocardial salvage assessed by Tc-99m sestamibi scintigraphy in patients with acute myocardial infarction after mechanical or thrombolytic reperfusion therapy. Circulation. 2002;105:2946-2949.
24. Fatah K, Beving H, Albage A, Ivert I, Blombäck M. Acetylsalicylic acid may protect the patient by increasing fibrin gel porosity. Is withdrawing of treatment harmful to the patient? Eur Heart J. 1996;17:1362-1366.
25. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA. 1987;258:1183-1186.
26. Lowe GD, Yarnell JW, Sweetnam PM, Rumley A, Thomas HF, Elwood PC. Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly Study. Thromb Haemost. 1998;79:129-133.